Sigma-Aldrich Reports Record Full-Year 2014 Sales

Sigma-Aldrich (NASDAQ – SIAL) Reports Record Full-Year 2014 Sales Of $2.79 Billion And Record Adjusted Diluted EPS Of $4.37. Reports Q4 2014 Adjusted Diluted EPS Of $1.14 And Organic Sales

Share
Merck, Sanofi, Syngenta & GSK announce full year results for 2014

Pharma giants Merck, Sanofi & GSK announced their full-year results for 2014 this week, as did global AgroChemical multinational Syngenta. Syngenta reported sales of $15.1 billion USD, achieving their integrates

Share
Thermo Fisher Strengthens Bioproduction Offering by Acquiring Advanced Scientifics

Thermo Fisher Scientific have announced their acquisition of ASI (Advanced Scientifics, Inc.) for a cash payment of $300 million USD as the company seeks to strengthen their bioproduction offerings. ASI

Share
Teixobactin Discovery Heralded as an Antibiotic Game Changer

Up until now uncultured bacteria have been an untapped source of new antibiotics, but promising research published in Nature yesterday highlights novel in-situ methods for growing uncultured microorganisms. One of

Share
Elsevier to Launch Open Access Multi-Disciplinary Scientific Journal

Academic publishing giant Elsevier have announced the forthcoming launch of a new open access multi-disciplinary scientific journal, calling for researchers to adopt a new collaborative and open source ethos. Dr.

Share
23andMe and Genentech Announce Research Partnership

Controversial DNA sequencing company 23andMe announced the first of 10 deals to be signed with large biotech and pharma firms on Tuesday January 6. Their $60 million partnership with Genentech

Share

BioReliance® Introduces Advanced In Vitro ADME and Toxicology Services Designed to Improve Drug Safety and Efficacy BioReliance® (www.bioreliance.com), Sigma-Aldrich Corporation’s (NASDAQ: SIAL) biologics and early-development services business under SAFC® Commercial

Share

Merck to Acquire Sigma-Aldrich to Enhance Position in Attractive Life Science Industry Merck to acquire Sigma-Aldrich for $140 per share in cash, valuing company at approx. $17 billion (€13.1 billion)

Share

Illumina Reports Record Financial Results for Third Quarter of Fiscal Year 2014 Illumina, Inc. announced its financial results for the third quarter of 2014. Third quarter 2014 results: Revenue of

Share

Lonza Half-Year Business Performance Fully on Track Business is fully on track with a CORE EBIT growth of 13.1% compared with the first half of 2013 despite currency headwinds Revenue

Share

QIAGEN demonstrates expanded bioinformatics workflows at ASHG; strong market adoption as researchers analyse genomic data on more than a quarter-million samples in secure private cloud Translational research in cancer and

Share

Roche delivers solid sales growth for the first nine months of 2014 Group sales up 5% at CER1, stable in Swiss francs 4% higher sales in Pharmaceuticals Division, with strong

Share